Kamada Ltd. announced multiple recent achievements related to CYTOGAM(R) (Cytomegalovirus Immune Globulin Intravenous [Human) (CMV-IGIV), which is indicated for the prophylaxis of CYTOGAM ("CMV") disease associated with transplantation of kidney, lung, liver, pancreas and heart, and is the sole U.S. Food and Drug Administration ("FDA") approved immunoglobulin (IgG) product for this indication. Kamada announced that CYTOGAM manufactured at the Company's facility in Beit Kama, Israel, is now available for commercial sales in the U.S. This follows the recent FDA approval of the technology transfer process of CYTOGAM from its previous manufacturer, CSL Behring. The advisory board focuses on Kamada's newly implemented U.S. clinical program for CYTOGAM including new opportunities and future research and development possibilities.

Minor reactions, such as ushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia, and wheezing, were the most frequent adverse reactions observed during the clinical trials for CYTOGAM.